LCM
JANX icon

Legato Capital Management’s Janux Therapeutics JANX Stock Holding History

Legato Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,479
Closed -$347K – 598
2024
Q4 		$347K Buy
+6,479
New +$343K 0.05% 484

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Legato Capital Management's JANX Position: Q1 2025 in Review

Legato Capital Management sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 6,479 shares — an estimated $347K sold.

Legato Capital Management first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $347K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Legato Capital Management reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Legato Capital Management sold 6,479 Janux Therapeutics shares in Q1 2025, an estimated $347K.
  • Legato Capital Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Legato Capital Management's Janux Therapeutics position peaked at $347K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Legato Capital Management's 13F filing for Q1 2025, filed 6 May 2025.